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Generating an anti-tumor immune response is a multi-step process that is executed by effector T cells that
can recognize and kill tumor targets. However, tumors employ multiple strategies to attenuate the effective-
ness of T-cell-mediated attack. They achieve this by interfering with nearly every step required for effective
immunity, from deregulation of antigen-presenting cells to establishment of a physical barrier at the vascu-
lature that prevents homing of effector tumor-rejecting cells and the suppression of effector lymphocytes
through the recruitment and activation of immunosuppressive cells such as myeloid-derived suppressor
cells, tolerogenic monocytes, and T regulatory cells. Here, we review the ways in which tumors exert immune
suppression and highlight the new therapies that seek to reverse this phenomenon and promote anti-tumor
immunity. Understanding anti-tumor immunity, and how it becomes disabled by tumors, will ultimately lead
to improved immune therapies and prolonged survival of patients.Introduction
The immune response against tumors is mounted by a multitude
of immune cells. However, T cells remain potent mediators of
anti-tumor immunity, and tumor infiltration by T cells is a good
prognostic marker in a number of tumor types, including ovarian,
colon, breast, renal, prostate, and cervical cancers (Galon et al.,
2006; Hwang et al., 2012; Ma et al., 2012; Naito et al., 1998;
Piersma et al., 2007; Zhang et al., 2003). The steps leading to
an antitumor immune response are depicted in Figure 1. In
some patients, these responses are activated spontaneously,
but chemotherapy is also thought to promote antitumor immune
responses.
Typically, the immune response begins at the tumor site,
where professional antigen-presenting cells (APCs) take up
tumor antigens to be processed. These antigens can be some
of the many mutational neo-antigens (Robbins et al., 2013), non-
mutated genes that are overexpressed by cancer cells, or differ-
entiation antigens related to the cancer’s tissue of origin (Segal
et al., 2008). Although T cell priming is traditionally thought to
occur exclusively in tumor-draining lymph nodes, spontaneously
organized tertiary lymphoid organ features can be also encoun-
tered in tumors (de Chaisemartin et al., 2011), suggesting that
T cell education can occur within the tumor stroma. Dendritic
cells from tumors might present antigens in a tolerizing manner,
stimulating T regulatory (Treg) cells (Steinman et al., 2000), which
would oppose an antitumor response. In order to promote immu-
nity rather than tolerance, it is believed that APCs require a
robust maturation signal. Toll-like receptor (TLR) signaling from
necrotic tumor cells can induce partial maturation (Cavassani
et al., 2008), but chemotherapy drugs that induce immunogenic
cell death can also stimulate an immune response (Zitvogel and
Kroemer, 2009). Activated dendritic cells can also drive B andNK
cell (Mellman and Steinman, 2001) responses that can play
important roles in antitumor immunity. The exact type of T cell
response required for optimal anti-tumor immunity is not entirely
clear, but a potent CD8+ effector T cell response is certainly
necessary. Additionally, a response directed by either CD4+T helper 1 (Th1) cells or Th17 cells appears to promote CD8+
effector T cell responses (Martin-Orozco et al., 2009; Mellman
and Steinman, 2001; Steinman et al., 2000). Given that tumor-
infiltrating lymphocytes (TILs) are such important prognostic
markers for tumor progression across multiple tumor types,
understanding the processes involved in their suppression
is essential to developing new therapeutic strategies. In this
review, we will detail the ways in which tumors suppress each
step in the generation of an effective anti-tumor immune
response; these range from generation of tumor-specific
T cells to their homing, engraftment, and effective recognition
of tumors. We also discuss recent and potential future therapeu-
tic interventions that might circumvent tumor-mediated immu-
nosuppression.
Generation of Tumor-Reactive T Cells
Dendritic cells (DCs) are extremely important for the coordination
of an anti-tumor immune response. As professional APCs, they
present tumor antigens to both B cells and T cells, generating
an antigen-specific antitumor response. Tumors have a profound
effect on the functions of dendritic cells (Gabrilovich, 2004).
Defective dendritic cell function is often combinedwith deregula-
tion of DC maturation, and in humans as well as in mice, tumor-
infiltrating cells expressing DC markers also express markers
of macrophages and immature monocytes, indicating recruit-
ment of myeloid precursors with incomplete differentiation
(Conejo-Garcia et al., 2004). Dendritic cells can have significant
heterogeneity both in vitro and in vivo (Hashimoto et al., 2011),
and they include resident and bone-marrow-derived myeloid
dendritic cells and plasmacytoid dendritic cells. These cells
have different functional properties, and they might contribute
differently to tumor tolerance or rejection (Kim et al., 2007). For
example, although DCs are important APCs, depletion of
CD11c+ cells (primarily DCs) can actually inhibit tumor growth
(Huarte et al., 2008), an effect that reflects the role of tumor-coop-
ted tolerogenic dendritic cells in establishing tumor tolerance and
dissemination (Labidi-Galy et al., 2011; Sawant et al., 2012).Immunity 39, July 25, 2013 ª2013 Elsevier Inc. 61
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Figure 1. Generation of an Anti-Tumor T Cell Response
Dendritic cells acquire tumor antigens from necrotic or apoptotic tumor cells
and then home to regional lymph nodes. Within the lymph nodes, DCs activate
T cells (and NK cells) and then traffic to the tumor site. Activated lymphocytes
cross the tumor endothelial barrier, recognize tumor targets, secrete cyto-
kines, and directly kill tumor targets. This process is under considerable
suppression from the tumors, which mount challenges that prevent optimal
T cell activation each step of the way. Within the tumor site, suppressive cells
such as Treg cells and MDSCs are recruited by tumors and actively prevent
lymphocytes from killing tumor targets.
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mature DCs expressing intermediate amounts of MHC class I
and II and costimulatory molecules, as well as high amounts of
coinhibitory molecules and immunosuppressive cytokines. In
the mouse, such cells are unable to elicit antigen-specific
effector T cells (Conejo-Garcia et al., 2004). Human DCs isolated
from breast, neck and/or head, and lung cancer patients were
also functionally impaired in a mixed leukocyte reaction, and
this functional impairment corresponded to a more severe
(higher stage) cancer diagnosis (Almand et al., 2000). Immature
or incompletely matured DCs might mediate tumor tolerance,
inducing anergy of effector T cells and/or expansion of Treg cells
in the lymph nodes or at tumor sites (Lutz and Schuler, 2002;
Mahnke et al., 2002).
Gabrilovich and colleagues were the first to identify vascular
endothelial growth factor (VEGF) as a tumor factor capable of im-
pairing both dendritic cell function and maturation from CD34+
hematopoietic precursors (Gabrilovich et al., 1996). Similar ob-
servations of defective DCs have since beenmade in association
with VEGF in cancer patients (Della Porta et al., 2005; Takahashi
et al., 2004). VEGF is an important regulator of hematopoiesis,
and its artificial overexpression has led to widespread changes
in the differentiation of multiple hematopoietic lineages. In pa-
tients, treatment with the VEGF-blocking antibody bevacizumab62 Immunity 39, July 25, 2013 ª2013 Elsevier Inc.has been shown to reverse DCmaturation defects (Almand et al.,
2000; Fricke et al., 2007; Osada et al., 2008). Defective DCmatu-
ration that is reversible with VEGF blockade was also found in
mouse models (Gabrilovich et al., 1999; Nair et al., 2003; Roland
et al., 2009; Ishida et al., 1998). VEGF most likely exerts effects
on dendritic cells beyond its role in the suppression of normal
hematopoiesis. Programmed death ligand 1 (PD-L1) is a major
negative regulatory ligand of the B7 family that engages the
cognate programmed death-1 (PD-1) receptor that is expressed
on activated T cells and which transduces a signal that inhibits
T cell proliferation, cytokine production, and cytolytic function
(Riley, 2009). PD-L1 is expressed on tumor cells, but it is also
highly expressed on tumor-associated myeloid DCs in ovarian
cancer patients (Curiel et al., 2003). Incubation of blood myeloid
DCs with VEGF induced robust expression of PD-L1 on the cell
surface, offering a potential mechanism by which VEGF might
affect DC function (Curiel et al., 2003).
A number of other tumor-derived soluble mediators can also
disrupt DC function and play critical roles in defining the semi-
mature, tolerogenic phenotype of tumor DCs. Such mediators
include transforming growth factor b (TGFb) (Geissmann et al.,
1999), interleukin 10 (IL-10) (Steinbrink et al., 1999), macrophage
colony-stimulating factor (M-CSF), and IL-6 (Menetrier-Caux
et al., 1998). IL-10 also induces PD-L1 expression on DCs (Curiel
et al., 2003). Additional mechanisms can contribute to a tolero-
genic phenotype for DCs. Physiological stimuli such as hypoxia
(Elia et al., 2008) and lactic acid (Gottfried et al., 2006) in the
tumor microenvironment can also influence DC phenotype and
function. In vitro, DCs differentiated under these exposures
tend to have a less mature phenotype, express immunosuppres-
sive molecules such as indoleamine 2,3-dioxygenase (IDO) and
prostaglandin E2 (PGE2), and fail to stimulate T cells efficiently
(Elia et al., 2008; Gabrilovich et al., 2012; Gottfried et al., 2006).
In particular, PGE2 signaling on DCs can induce the expression
of immunosuppressive molecules such as IL-10 (Kalinski et al.,
1997) and IDO (Braun et al., 2005), suppress IL-12 production
(Watchmaker et al., 2010), and inhibit chemokine expression
(Muthuswamy et al., 2010).
Thus, it is not surprising that in many patients there are no
detectable tumor-reactiveTcells. Forexample, inovariancancer,
tumor-reactiveTcellsweredetectedintheperipheralbloodofonly
half the patients tested (Schlienger et al., 2003). The defective
phenotype of DCs might contribute further to deregulation of the
T cell tumor attack; properly mature DCs that express costimula-
tory ligandsmight be required in theperiphery at the inflammatory
site to maintain an effective effector CD8+ T cell response (Dolfi
et al., 2011), and these are typically absent in the tumor microen-
vironment. Finally, defective DCs fail to secrete appropriate
chemokines that play a critical role in recruiting effector cells to
tumors(Muthuswamyetal.,2012).Asdescribedabove,disruption
of normal DC function is an essential component of tumor-medi-
ated immune suppression that leads to tumor immune tolerance,
and strategies aimed at relieving this immune suppression or
generating potent DC-vaccines ex vivo are an active area of
research that has already enjoyed some early success.
Reaching the Tumor Site
Tumors have developed a number of unique ways to sup-
press the recruitment of T cells to the tumor site. The exact
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Figure 2. Tumor Endothelium in Immune Suppression
(A) The endothelium is a physical barrier to T cell trafficking. During the normal
inflammatory response, TNFa upregulates adhesion molecules ICAM and
VCAM.While rolling, T cells bind to the adhesion molecules through LFA-1 and
VLA-1, then extravasate through the endothelium and home to the site of
inflammation. In the tumor microenvironment, tumor-derived angiogenic
growth factors such as VEGF and ET-1 signal through their cognate receptors
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normal chemokine elaboration is believed to be a contributing
factor. Chemokines play a critical role in orchestrating T cell traf-
ficking and the specialization of immune responses, and their
alteration is probably tissue specific. Of particular interest is
the observation that tumors with high numbers of T cells express
high amounts of established T-cell-attracting chemokines,
including chemokine (C-C motif) ligand 2 (CCL2), CCL3, CCL4,
CCL5, chemokine (C-X-C motif) ligand 9 (CXCL9), and CXCL10
(Harlin et al., 2009). It is unclear whether this is the result of an
initial T cell activation, unleashing a chemokine response
furthering T cell recruitment. However, the pattern of T cell infil-
tration in mouse models suggests that a few T cells infiltrate
tumors initially and that a large influx of both specific and
nonspecific T cells follows (Boissonnas et al., 2007). In skin
tumors, aberrant epidermal growth factor receptor (EGFR)-Ras
signaling has been shown to suppress the production of
CCL27, a chemokine constitutively expressed by normal kerati-
nocytes, and disruption of CCL27 expression in vivo prevented
T cell homing to skin tumors and accelerated tumor outgrowth
in a mouse model (Pivarcsi et al., 2007).
Tumor cells are well known for aberrant post-translational
modifications, and changes in cleavage, glycosylation, or deam-
ination could result in dramatically altered activities of expressed
chemokines (Loos et al., 2009; Proost et al., 2007). For example,
CCL2, an important chemokine for the recruitment of cytotoxic
lymphocytes (CTLs) to the tumor site (Brown et al., 2007),
undergoes nitrosylation induced by reactive nitrogen species,
and this nitrosylation abrogates CCL2’s ability to attract
tumor-specific CTLs, although it can still attract myeloid cells
(myeloid-derived suppressor cells; MDSCs) to the tumor (Molon
et al., 2011), highlighting a potent mechanism of immune
suppression. Furthermore, altered proteolytic processing of
CXCL11, an important chemokine that recruits CXCR3+ effector
T cells, can impair binding and signaling of the chemokine and
ultimately reduce lymphocyte migration (Boissonnas et al.,
2007; Harlin et al., 2009; Proost et al., 2007). Thus, deregulation
of chemokine circuitries appears to be an important mechanism
preventing proper orchestration of immune tumor-rejection
mechanisms.
Crossing the Tumor Vasculature
Although T cells can accumulate in the tumor stroma, they often
fail to penetrate deeply into tumors in the epithelial compartment
(Zhang et al., 2003; Boon et al., 2006; Dudley et al., 2002; Lurquin
et al., 2005). The vascular endothelium plays a key role in leuko-
cyte trafficking, and mounting evidence indicates that the tumor
vasculature establishes an active barrier that tumor-reactive
T cells must cross in order to recognize and eliminate their tumor
targets (Figure 2) (Boon et al., 2006; Dudley et al., 2002; Lurquinon the endothelium and block the expression of adhesion molecules, pre-
venting T cell infiltration.
(B) The endothelium is a direct modulator of immune suppression. Under the
influence of tumor- and stroma-derived factors (e.g., VEGF), the tumor
endothelium expresses a number of immunosuppressive molecules such as
TIM-3, IDO, PDL1/2, and PGE2. The expression of these molecules limits
effector T cell activation. Furthermore, the endothelium can also express a
number of genes (e.g., TRAIL) that can directly kill effector T cells as they
attempt to transverse the endothelial barrier.
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thelial barrier is required for optimal tumor regression. The pro-
hibitive nature of the tumor endothelium can be mediated by
the type and quantity of adhesion molecules expressed (Zitvogel
et al., 2006) and is presumably maintained by local soluble tumor
factors (Zitvogel et al., 2006), but precisely how the tumor vascu-
lature establishes immune privilege is not well known.
T cells extravasate through the endothelium to the tumor in
multi-step process that includes rolling and adhesion to endo-
thelial cells and subsequent diapedesis. Although the precise
mechanisms are not entirely known, the consensus view is that
in the tumor microenvironment angiogenic molecules, including
VEGF, inhibit adhesion molecule expression on endothelial cells
(Bouzin et al., 2007; Detmar et al., 1998; Dirkx et al., 2003; Grif-
fioen et al., 1996a; Griffioen et al., 1996b;Min et al., 2005). Tumor
necrosis factor-alpha (TNFa) is often expressed within the tumor
microenvironment and is expressed, albeit in low amounts, by
many malignant cells (Balkwill, 2009). Although TNFa is an acti-
vator of endothelial cells and T cell adhesion, in the presence of
angiogenic growth factors such as basic fibroblast growth factor
(bFGF) or VEGF (Bouzin et al., 2007; Griffioen et al., 1996b),
TNFa-induced T cell adhesion is minimal. In the presence of
VEGF, TNFa stimulation is unable to induce expression of inter-
cellular adhesion molecule-1 (ICAM-1) and vascular cell adhe-
sion molecule (VCAM-1) on endothelial cells (Bouzin et al.,
2007; Griffioen et al., 1996b).
Endothelins and their receptors are upregulated in a number of
cancers, including ovarian, breast, renal, colon, and prostate
cancer (Bagnato and Rosano`, 2008; Nelson et al., 2003). Endo-
thelin (ET) peptide ligands ET-1, -2, -3, and -4 (Saida et al., 1989;
Yanagisawa andMasaki, 1989) are potent regulators of endothe-
lial cell biology and are involved in autocrine and paracrine loops
that promote proliferation, protection, from apoptosis, angio-
genesis, vasculogenesis, and invasion and metastatic dissemi-
nation of tumors (Bagnato and Rosano`, 2008; Nelson et al.,
2003). Endothelins signal through two G-protein-coupled recep-
tors (GPCR), the endothelin-A receptor (ETAR) and ETBR, which
exert opposite effects on the vasculature (Frommer and Mu¨ller-
Ladner, 2008; Meidan and Levy, 2007). The use of specific endo-
thelin receptor antagonists has been demonstrated to slow
tumor growth in patients and to prevent tumor growth in mouse
models (Bagnato and Rosano`, 2008; Nelson et al., 2003). Endo-
thelins interact with VEGF to regulate multiple aspects of
angiogenesis, including endothelial cell proliferation, migration,
invasion, vessel formation, and neovascularization (Nelson
et al., 2003). ET-1 can directly promote the expression of
VEGF in cancer cell lines in vitro (Rosano` et al., 2003; Salani
et al., 2000; Spinella et al., 2007; Spinella et al., 2002), most likely
through increased HIF-1a expression (Salani et al., 2000).
Furthermore, there is a correlation between ETBR and VEGF
expression in a number of different tumor specimens (Kato
et al., 2001). In addition to regulating vascular tension and angio-
genesis, ETBR was recently demonstrated to suppress endothe-
lial adhesion and T cell infiltration in tumors (Buckanovich et al.,
2008). Endothelial ETBRwas upregulated in ovarian tumors lack-
ing intraepithelial tumor-infiltrating lymphocytes (TILs) (Bucka-
novich et al., 2008) and, similar to the absence of intraepithelial
TILs (Zhang et al., 2003), ETBR overexpression was associated
with poor survival. Endothelin 1 (ET1) signaling through ETBR64 Immunity 39, July 25, 2013 ª2013 Elsevier Inc.was found to block T cell adhesion to the endothelium through
suppression of ICAM-1 clustering on endothelial cell membranes
(Buckanovich et al., 2008). ET1 is overexpressed in ovarian can-
cer (Bagnato et al., 1999), establishing a paracrine axis involving
tumor cells, endothelium ET1, and ETBR expressed by the endo-
thelium; this axis is upregulated specifically in the tumor micro-
environment and suppresses T cell adhesion to endothelium,
even in the presence of increased TNFa.
The imunosuppressive effects of VEGF as well as those of
ETBR on tumor endothelium appear to be commonly mediated
by nitric oxide (NO) given that specific NO antagonists can abro-
gate the deregulation of CAMs induced by either molecule and
restore T cell adhesion (Buckanovich et al., 2008; Bouzin et al.,
2007). NO is a gaseous molecule and a highly reactive free
radical. NO is highly important in the control of vascular functions
regulating angiogenesis, vascular permeability, blood flow, and
leukocyte-endothelial interactions (Fukumura et al., 2006). In
tumors, inhibition of the NO-producing enzyme, nitric oxide syn-
thase (NOS), enhanced both rolling and adhesion of leukocytes
on tumor vasculature (Fukumura et al., 1997). Although this
effect might be due in part to direct effects of NO on T cells (Lu-
kacs-Kornek et al., 2011; Bronte et al., 2005), NO also directly
affects endothelial cells in a manner that might limit anti-tumor
immunity. NO reduces leukocyte-endothelial interactions by
reducing the expression of important adhesion molecules P-
selectin, ICAM-1, and VCAM-1, and conversely, NOS inhibitors
increase expression of these adhesion molecules and leukocyte
binding in normal blood vessels (De Caterina et al., 1995; Daven-
peck et al., 1994; Kubes et al., 1991). Furthermore, mice genet-
ically deficient in the enzymes responsible for NO synthesis
displayed enhanced leukocyte-endothelial interactions driven
by P-selectin (Lefer et al., 1999).
It is emerging that the tumor vasculature also can shape the
nature of T cell infiltration in tumors thorough mechanisms inde-
pendent of adhesive interactions. Endothelial cells can, for
example, express a number of mediators that suppress or kill
effector lymphocytes. Such mediators include Fas ligand
(FasL) (Sata and Walsh, 1998), TNF-related apoptosis-inducing
ligand (TRAIL) (Secchiero and Zauli, 2008), and possibly even
CD31, a classical endothelial cell marker (Ma et al., 2010). Tumor
endothelial cells can also express a robust repertoire of immuno-
suppressive molecules, both soluble and surface expressed,
including PD-L1 and PD-L2 (Frebel et al., 2012; Mazanet and
Hughes, 2002; Rodig et al., 2003), B7-H3 (Zang et al., 2010),
TIM-3 (Huang et al., 2010), IL-10, TGFb, and PGE2 (Herna´ndez
et al., 2001; Pirtskhalaishvili and Nelson, 2000). Metabolic
disruption of T cells through IDO expression (Batista et al.,
2009; Blaschitz et al., 2011; Riesenberg et al., 2007) and arginase
I (Fu et al., 2011) by endothelial cells has also been suggested,
but whether these mechanisms are active in tumors are
unknown. Thus, the function of tumor endothelial cells is largely
immunosuppressive and is maintained by tumor cells through
paracrine mechanisms (Mulligan et al., 2009; Mulligan and
Young, 2010).
Negotiating the Tumor Stroma Space and Suppressive
Leukocytes
The effector T cells that manage to cross the endothelial barrier
must navigate the tumor stroma until they encounter tumor cell
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sive signals exist within this space. Although resident stromal
and immune cells can certainly contribute to immune suppres-
sion within the tumor microenvironment (Aggarwal and Pit-
tenger, 2005; Dranoff and Fearon, 2013; Engels et al., 2012;
Kammertoens et al., 2005; Motz and Coukos, 2011), immuno-
suppressive leukocyte populations such as Treg cells (Faccia-
bene et al., 2012) and MDSCs (Gabrilovich and Nagaraj, 2009)
are also actively recruited and undergo local expansion to effec-
tively suppress T cell effector functions. Infiltration of these cells
types is frequently associated with a poor prognosis.
CD4+CD25+FoxP3+ Treg cells can be divided into natural Treg
(nTreg) cells, which are derived from the thymus and maintained
peripherally by TGFb, and inducible Treg (iTreg) cells, which are
induced from naive CD4+ T cell precursors and exert suppres-
sive functions similar to those observed for nTreg cells; these
functions are controlled in both Treg subtypes by the forkhead
box P3 (FoxP3) transcription factor (Curotto de Lafaille and La-
faille, 2009). Several studies have determined that Treg cells
that accumulate within tumors are generally clonally restricted
(Sainz-Perez et al., 2012) and are specific for tumor antigens
(Bonertz et al., 2009); they express different T cell receptor
(TCR) sequences than local effector T cells (Sainz-Perez et al.,
2012). Treg cells are thus activated in an antigen-specificmanner
but can suppress T cell function nonspecifically through several
mechanisms (Facciabene et al., 2012; Vignali et al., 2008). Treg
cells secrete soluble mediators such as TGFb, IL-10, and IL-
35, which can suppress effector T cell expansion and cytokine
(IFNg, TNFa) secretion. Specifically, TGFb and IL-10 have been
shown experimentally to make significant contributions to tumor
progression by attenuating antitumor immunity (Loser et al.,
2007; Strauss et al., 2007). Although IL-2 signaling on Treg cells
is not required for their suppressive function, Treg cells require
IL-2 support to maintain metabolic homeostasis and their
competitive fitness in vivo, (Fontenot et al., 2005). Thus, Treg
cells depend on paracrine support from T effector cells, which
secrete IL-2, for expanding and maintaining local tolerance. It
is also believed that because of higher expression of the IL-2
receptor alpha (IL-2Ra, also known as CD25), Treg cells can
act as an IL-2 sink, ‘‘starving’’ effector T cells of IL-2 particularly
within the tumor microenvironment and thus limiting effector
T cell expansion and function (Pandiyan et al., 2007). In addition,
Treg cells can suppress CTLs through the generation of adeno-
sine (Deaglio et al., 2007). Treg cells can also directly kill T cells
via cytolysis mediated by TRAIL (Ren et al., 2007) or granzyme B
(Gondek et al., 2005). Finally, Treg cells can engage in crosstalk
with DCs, inducing the expression of IDO, IL-10, and TGFb
expression from DCs through direct interactions (Facciabene
et al., 2012).
Treg cells are actively recruited by tumors, and their accumu-
lation has been associated with poor prognosis in some studies
(Curiel et al., 2004). Chemokine ligand CCL22 is a potent Treg
chemoattractant expressed in high amounts by both tumor cells
and tumor macrophages recruiting Treg through C-C chemokine
receptor 4 (CCR4) in ovarian cancer (Curiel et al., 2004) and
Hodgkin’s lymphoma (Ishida et al., 2006). Recently, a link
between Treg recruitment and hypoxia was discovered in
ovarian cancer. Hypoxic ovarian cancer cells were shown to
preferentially upregulate CCL28 among all chemokines (throughhypoxia-inducible factor), and this CCL28 upregulation recruited
CD4+CD25+FoxP3+ Treg cells through the cognate receptor
CCR10 expressed preferentially on Treg cells among T cell sub-
sets (Facciabene et al., 2011). Forced overexpression of CCL28
in mouse ovarian cancer cells led to enhanced growth of intra-
peritoneal tumors, characterized by increased Treg infiltration
and accelerated tumor growth (Facciabene et al., 2011). Of
importance, depletion of CD25+ or CCR10+ cells eliminated
Treg cells from CCL28-overexpressing tumors and abrogated
the tumor growth advantage conferred by CCL28 overexpres-
sion. It was found that besides immune suppression, CCL28-
recruited Treg cells reprogrammed the tumor microenvironment
toward angiogenesis (Facciabene et al., 2011). Recruitment of
Treg cells to areas of hypoxia could enhance their immunosup-
pressive capacity because hypoxia-exposed Tregs are more
effective at suppressing the proliferation of effector T cells
(Ben-Shoshan et al., 2008).
In addition to recruiting nTreg cells, the tumor microenviron-
ment promotes the continued expansion of nTreg cells (Valza-
sina et al., 2006) as well as the generation of iTreg cells (Liu
et al., 2007). It is believed that IL-10 (Seo et al., 2001), TGFb
(Chen et al., 2003), and adenosine (Zarek et al., 2008) derived
from either tumor cells or tumor-resident immunosuppressive
DCs (Ghiringhelli et al., 2005) and Tie-2+monocytes (TEMs) (Cof-
felt et al., 2011; Liu et al., 2007) might be responsible for this.
Furthermore, TEMs can expand Treg cells in vitro in a CD86-
dependent manner, and in breast cancer patients TEMs
expressing high amounts of CD86 are associated with high
numbers of Treg cells (Ibberson et al., 2013). CD86 expression
in TEMs is dependent on TIE-2 and VEGFR signaling in vitro
(Ibberson et al., 2013), highlighting the contribution of angiogen-
esis to this phenomenon.
There are a number of myeloid lineage cells that accumulate
within tumors, but perhaps the best studied are MDSCs. These
cells are often found in large numbers within tumor sites as
well as in the peripheral blood of cancer patients, and they are
potent inhibitors of effector T cell functions (Gallina et al.,
2006). These cells can contribute to the suppression of T cells
through the production of arginase I and reactive oxygen species
(ROS), IL-10, and TGFb (reviewed by [Gabrilovich and Nagaraj,
2009]). Additionally, MDSCs can expand Treg cells within the
tumor site (Huang et al., 2006). MDSCs can be recruited from
the bone marrow and expanded in the peripheral blood through
interactions with BV8 and endocrine-gland-derived VEGF (EG-
VEGF) (LeCouter et al., 2004; Lin et al., 2002; Shojaei et al.,
2007). Once in the blood, MDSCs can be recruited to tumors
by a number of chemokines, such as CCL2, CXCL5, CXCL12,
and stem cell factor (SCF) (Murdoch et al., 2008). The expression
of both BV8 and CXCL12 is increased by hypoxia (Du et al.,
2008), so in a similar manner to Treg cells, MDSCs might be
recruited to sites of tumor hypoxia, where they might directly in-
fluence angiogenesis. Once in the tumor, MDSCs exert potent
effects on T cell effector function, but they also control other
key events in tumors. Injection of MDSCs into tumors signifi-
cantly enhanced blood vessel development (Yang et al., 2004),
and tumor angiogenesis was reduced in tumor-bearing mice
treated with a neutralizing anti-BV8 antibody that reduced the
numbers of infiltrating MDSCs (Shojaei et al., 2007). However,
MDSCs have been shown to have phenotypic plasticity, andImmunity 39, July 25, 2013 ª2013 Elsevier Inc. 65
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Figure 3. Local Immune Suppression in the Tumor
Microenvironment
After arrival within the tumor microenvironment, effector T cells can recognize
and kill tumor targets. However, a number of soluble mediators, including
TGFb, IL-10, and adenosine, that are secreted by Treg cells, MDSCs, and
tumor cells can limit T cell effector functions. It is likely that tumor cells over-
express these molecules as a result of transformation, but Treg cells can be
activated upon CTLA-4 ligation with CD80 on local APCs. In addition, tumors
and Treg cells can disrupt effector T cell functions through metabolic disrup-
tion through tryptophan (mediated by IDO expression) and IL-2 depletion.
Furthermore, PD-L1 and -L2 expression on tumor cells can directly terminate
effector T cell functions through the ligation of PD-1 expressed by T cells.
Immunity
Reviewthey can acquire the characteristics of tumor-rejecting mono-
cytes and even APCs if the right conditions are met. For
example, cytokines such as IL-12 and IFNg have been shown
to convert MDSCs into an APC-like cell that activates and en-
hances the functions of T cells either in vitro (Bronte et al.,
2000) or in vivo (Kerkar et al., 2011).
The Encounter with Tumor Cells
After T cells finally make their way through the barriers of the
tumor vasculature and stroma, they are faced with a number of
immunosuppressive factors that prevent effective recognition
and/or attack of tumor cells (Figure 3). This topic has been re-
viewed extensively elsewhere (Whiteside, 2006; Zou, 2005).
T cells depend largely on recognition of targets through major
histocompatibility complex (MHC)-TCR interactions. It has
become quite obvious that tumors express unique protein prod-
ucts that can be recognized by the immune system as "non-self";
such products range from overexpressed self-proteins,
including cancer testis and other immune-privileged site anti-
gens, to novel mutational epitopes resulting from nonsynony-
mous somatic mutations. Most tested tumors harbor tens to
hundreds of such mutations (Vogelstein et al., 2013), many of
these epitopes are candidates for presentation (Segal et al.,
2008), and T cells recognizing such tumor-rejection epitopes
have been recently identified in melanoma (Robbins et al.,
2013), but it is not known whether these mutations are in fact
transcribed, translated in mutated protein products, or finally
included in peptides presented on surface MHC molecules in66 Immunity 39, July 25, 2013 ª2013 Elsevier Inc.all tumors. Many tumors presumably manage to eliminate the
presentation of immunogenic peptides through loss of expres-
sion or downregulation of the antigen-presenting machinery
occurring in both MHC Ia (classical) (Marincola et al., 2000)
and MHC Ib (nonclassical) presentation (Carosella et al., 2003;
Rodgers and Cook, 2005). There are a multitude of mechanisms
responsible for this aberrant expression, possibly stemming
from selective pressure from mutation, genetic loss, or epige-
netic silencing of expression (Chang et al., 2005). This reduction
is associated with histopathological markers of poor prognosis
of disease and poor clinical outcomes (Marincola et al., 2000).
However, the demonstration that CD8+ T cells recognizing muta-
tional epitopes are already present in tumors and can in fact
reject tumors under the optimized conditions of adoptive trans-
fer, indicates that at the steady-state tumors manage to atten-
uate recognition and attack by these T cells (Carosella et al.,
2003; Chang et al., 2005;Marincola et al., 2000). Tumors express
surface molecules that can directly kill T cells; these molecules
are expressed in particular by the TNF family of genes that
include FasL and TRAIL (Whiteside, 2002). They can also
express surface proteins such as PD-L1, PD-L2 (Hamanishi
et al., 2007), and B7-H4 (Kryczek et al., 2006), which can sup-
press T cell functions and arrest tumor rejection (Hirano et al.,
2005; Munn and Mellor, 2004; Whiteside, 2002). In addition,
the microenvironment close to tumor cells may be quite toxic
for optimal CTL function. Tumors secrete a number of soluble
mediators, such as TGFb, IL-10, PGE2, histamine, hydrogen
peroxide, and adenosine (Whiteside, 2002), that can directly
inhibit CTLs. Deprivation of metabolic substrates as a result of
competitive consumption by tumor cells and/or active depletion
by enzymes such as IDO and arginase (Munn and Mellor, 2004)
can further attenuate T cell effector function. Finally, the hypoxic
conditions (Palazo´n et al., 2012) and the relatively lower extracel-
lular pH characterizing the tumor interstitium can negatively
affect CTL function (Aggarwal and Pittenger, 2005; Mendler
et al., 2012).
Therapies to Restore Antitumor Immunity
The generation of competent tumor-specific CTLs and their
recognition and rejection of tumor cells seems like an impossible
task. Yet recent successes indicate that this can be achieved
with existing therapeutic means in a proportion of patients. It is
obvious that most—if not all—tumors are potentially immuno-
genic, but the endogenous immune response is either entirely
paralyzed or ineffective. Thus, major efforts should focus on
attenuating tumor-associated immune suppression. Presently,
there are multiple opportunities to target immunosuppressive
pathways and mobilize antitumor immunity in vivo or ex vivo.
Effective antitumor T cells can be expanded ex vivo from natural
TILs, from endogenous high-avidity T cell clones recognizing
tumor-associated antigens, or from T cells transduced with
exogenous cloned TCRs or chimeric antigen receptors (CARs),
and the host can be conditioned by lymhodepletion so that their
engraftment is optimized; endogenous T cells can also be effec-
tively activated by pharmacologic checkpoint inhibitors; the
vasculature can be disrupted by low-dose metronomic chemo-
therapy or normalized by drugs targeting angiogenesis; soluble
immunosuppressive factors such as IDO, IL-6, IL-10, TGFb,
and PGE2 can be individually blocked by specific pharmacologic
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therapy drugs such cyclophosphamide (e.g., for Treg cells) or
gemcitabine (e.g., for MDSCs); endogenous tumor-specific
T cell immunity can be effectively boosted by exogenous vac-
cines; and tumor-associated antigen-presenting cells can be
activated by specific drugs, including Toll-like receptor agonists,
while tumor antigens can be released in situ by immunogenic cell
death induced by specific chemotherapy drugs or radiation. The
complexity of the immunosuppressive mechanisms at the tumor
microenvironment and the availability of multiple therapeutic
opportunities render the clinical advancement of cancer immu-
notherapy strategies a daunting task. The rational design of ther-
apeutic strategies could be aided by tumor classification based
on the presence of pre-existing immunity. Robust biomarkers of
pre-existing tumor immunity have not been validated yet, but
TILs demonstrated by immunostaining could be a reasonable
biomarker for classifying tumors in those that already have
pre-existing TILs as well as in those that do not. Because most
clinical trials lack pretreatment biopsies, there is to date no avail-
able data on whether the TIL biomarker can predict responses to
checkpoint blockade or other therapies activating T cells (such
as bispecific antibodies). However, this classification could
help in the design of immunomodulatory therapy because
immune escape mechanisms are likely to be quite different
between these two main tumor immunophenotypes, at least
with respect to T cell homing and engraftment. Validation of
TILs is urgently needed so that it can be determined whether
their presence in human tumors is a robust indication of endog-
enous antitumor immune response. Below, we discuss a number
of immune therapies that have shown clinical efficacy or are
under clinical development.
Tumors with Pre-existing TILs
In tumors with pre-existing TILs, one can assume that the tumor
microenvironment does not offer major barriers to T cell homing.
Furthermore, the detection of tumor-reactive TILs would provide
a strong indication that the tumor microenvironment does not
entirely paralyze antigen-presenting mechanisms or the engraft-
ment of tumor-reactive T cells. In melanoma, the success of
adoptive TIL therapy is a testament to this hypothesis; all
patients who receive TILs are preselected on the basis of the
availability of expandable tumor-reactive TILs, and a significant
proportion of them experience objective responses. Thus, these
TILs can reject tumors when appropriately activated and
expanded, indicating that proper T cell activation is amajor issue
in these tumors and that mechanisms limiting the function of
CTLs must be operating in these tumors at the steady state.
Attenuation of these immunosuppressive mechanisms could
lead to clinical responses in many of these tumors. The first
convincing evidence that activation of CTLs could produce
objective clinical benefit in a significant number of patients was
provided by Ipilimumab, a monoclonal antibody directed against
CTLA-4 (cytotoxic T lymphocyte activation marker 4). CTLA-4 is
a potent negative regulator of T cell activation and binds tomem-
bers of the B7 family of costimulatory molecules (Chambers
et al., 2001). Binding of CTLA-4 inhibits activation of T cells,
thus attenuating excessive T cell activation. The significance of
CTLA-4 as a negative regulator of the immune response comes
from CTLA-4 knockout mice, which die at a very early age of
autoimmune toxicity (Waterhouse et al., 1995). Ipiliumab hasshown an overall survival benefit in two randomized phase III
trials in patients with advanced melanoma (Hodi et al., 2010;
Robert et al., 2011). Although the response rates were
modest—between 10% and 15%—a significant survival advan-
tage was observed in the treated populations. The mechanisms
of action of CTLA-4 blockade, including disinhibition of CTLA-4+
tumor-reactive TILs, but also depletion of CTLA-4high activated
Treg cells, are still debated (Egen et al., 2002; Kwon et al.,
1999; Selby et al., 2013; Sutmuller et al., 2001; van Elsas et al.,
2001).
PD-1 is an additional coinhibitory receptor expressed on acti-
vated T cells. Its function is important in peripheral tissues, where
T cells can encounter the PD-1 ligands PD-L1 (B7-H1) and PD-L2
(B7-DC), which are expressed by tumor cells, stromal cells, or
both (Dong et al., 2002). Inhibition of PD-1 signaling can enhance
T cell responses both in vitro and in vivo in preclinical tumor
models (Iwai et al., 2002). In complementary pilot clinical studies
using either anti-PD1 or anti-PD-L1 antibody, a large number of
patients have demonstrated objective clinical responses
(Brahmer et al., 2012; Topalian et al., 2012). Patients who
responded the most appeared to be those whose tumors
expressed PD-L1. In addition to patients with melanoma and
renal cell cancer, those with lung cancer and other solid tumors
have shown objective responses, validating that tumor immuno-
genicity is a universal tumor property and it is not restricted to a
few tumor types traditionally considered to be immunogenic. A
variety of additional coinhibitory (LAG-3, TIM-3, BTLA, 2B4,
KLRG-1, CD160, etc.) and costimulatory (CD28, 4-1BB, OX-40,
GITR etc.) receptors have been identified. Their significance as
therapeutic targets, whether complementary or redundant, will
require careful preclinical characterization and clinical testing.
Despite encouraging preclinical results with dual blockade of
PD-1 and CTLA-4 (Duraiswamy et al., 2013), clinical data are still
being accumulated (trial number NCT01024231). However, the
fact that many patients still do not respond to CTLA-4 and/or
PD-1 blockade may suggest that additional signals are required
for the effective rescue of TIL function.
An additional approach to activating TILs is the use of bispe-
cific antibodies. This approach relies on the use of dual-speci-
ficity recombinant antibody structures that simultaneously
engage both the TIL and an antigen on the tumor cell surface
(Kontermann, 2012). For example, a recent approach using a
bispecific antibody that recognizes both CD3ε (T cell activating
domain) and CD19 (tumor-binding domain) achieved impressive
clinical success (Topp et al., 2011). This approach could be used
in a number of additional tumor targets to promote activation of
TILs within the tumor microenvironment. This method activates
TILs in a nonspecific manner and therefore does not rely on
the presence of endogenous tumor-specific T cells. However,
tumors with pre-existing TILs might be more prone to respond,
given that TILs are already available at the tumor microenviron-
ment and that homing of additional T cells is not prevented by
obvious local barriers.
Tumors Lacking Pre-existing TILs
Whereas tumors with pre-existing TILs appear to be intrinsically
more immunogenic and easier to approach therapeutically,
tumors lacking TILs might be more complex. Experiments in
mice indicate that effective checkpoint blockade might not be
sufficient to reenact tumor rejection mechanisms, and additionalImmunity 39, July 25, 2013 ª2013 Elsevier Inc. 67
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of antitumor immunity (Kwon et al., 1999; Sutmuller et al.,
2001; van Elsas et al., 2001). The molecular basis of immune
escape in these tumors might be downregulation of the anti-
gen-presenting machinery in tumor cells; this downregulation
could be due to epigenetic deregulation and can be reversed
with histone deacetylase inhibitors (Magner et al., 2000) or the
use of low-dose IFNg (Propper et al., 2003). Alternatively, a pro-
hibitive tumor endothelial barrier could explain why T cells might
not be able to home to tumors (Kandalaft et al., 2011). Proangio-
genic signals can deregulate adhesive properties of the tumor
endothelium, and thus antiangiogenesis therapy could con-
tribute to the antitumor immune response (Motz and Coukos,
2011). VEGF blockade in a transgenic mouse model of Her2/
neu-driven breast cancer induced a de novo TIL infiltrate, which
was responsible for enabling the therapeutic efficacy of VEGF
blockade, as shown by the fact that CD8+ T cell depletion abro-
gated the therapeutic efficacy of the anti-VEGFR-2 antibody
DC101 (Manning et al., 2007). Given that VEGF inhibition has
not proven beneficial in many human solid tumor types (Ebos
and Kerbel, 2011), alternate or combinatorial approaches to
blocking angiogenesis might be required. Lastly, given the likely
paucity of pre-existing T cells in these tumors, maneuvers that
expand the pool of tumor-specific T cells could prove beneficial.
Molecularly definedmonovalent vaccines have failed to produce
substantial responses to date, but whole-tumor antigen vac-
cines have performed better (Neller et al., 2008) and can greatly
enhance checkpoint blockade to produce effective rejection of
nonimmunogenic tumors (Duraiswamy et al., 2013). This is
possibly because they comprise all the potential mutational
epitopes in addition to any other immunodominant epitopes.
Future vaccine development based on mutational epitopes will
test this hypothesis (Castle et al., 2012). Alternatively, in situ
vaccination with exposure of tumor antigen through the use of
immunogenic chemotherapy or radiation, in combination with
tumor APC activation using appropriate Toll-like receptor ago-
nists, could lead to the generation of tumor-reactive T cells
and a switch of the tumor chemokine microenvironment by acti-
vated innate immune cells.
Specific Targeting of Immunosuppressive Cells
In addition to promoting the activity of anti-tumor T cells, a num-
ber of approaches are aimed at inhibiting immune suppression
within the tumor microenvironment. Specifically, a number of
therapies have been developed to specifically deplete major
immunosuppressive cell types. Reviewed extensively by Faccia-
bene and colleagues (Facciabene et al., 2012), a number of
direct and indirect methods aimed at depleting Treg cells within
the tumor microenvironment exist. These include specific deple-
tion with monoclonal antibodies (anti-CD25) and depletion with
the use of chemotherapeutics such as cyclophosphamide (Fac-
ciabene et al., 2012). Furthermore, additional immune cell tar-
gets such as MDSCs have shown preclinical successes (Shojaei
et al., 2007). This remains an area of active research.
Facing and Deconvoluting the Molecular Complexity of
Tumor Immune Suppression
After decades of disappointment in immunotherapy, cancer
immunotherapy using adoptive transfer of T cells or therapeutic
antibodies that neutralize key checkpoint mechanisms (e.g.,68 Immunity 39, July 25, 2013 ª2013 Elsevier Inc.CTLA-4 or PD-1) has finally met the long-standing expectation
that it will result in significant and reproducible clinical benefits.
Immunotherapy is thus a feasible path forward to obtaining dura-
ble, long-lasting responses in cancer patients. Yet, many
patients fail to respond, and among those who respond, many
do not draw long-lasting benefits. Whereas adoptive therapy
requires sophisticated infrastructures, checkpoint antibody
therapy can be more easily distributed. Unfortunately, the
mechanisms underlying therapeutic resistance to checkpoint
blockade agents remain poorly understood, and the field faces
a major gap in knowledge between our present understanding
of mechanisms of tumor immune evasion at the steady state
and tumor resistance to immunomodulatory therapy. It is likely
that checkpoint blockade fails because constitutive or adaptive
tolerance mechanisms suppressing antigen presentation and/
or T cell homing and function are so powerful in many tumors
that they cannot be overcome solely by checkpoint blockade.
A major challenge in addressing these mechanisms relates to
the complexity of tumor microenvironment immunoregulatory
systems, where tumor cells and an ever-growing list of tumor-
infiltrating host leukocytes and stromal cells (including blood
and lymphatic endothelial cells and fibroblasts) can block
T cell homing, engraftment, or effector function by diverse but
often overlapping mechanisms. To translate this knowledge for
use in the development of rational (and personalized) therapies,
one must develop knowledge and tools that allow integrating
these pathways and deciphering their functional order and hier-
archies (if any exist). For example, at the steady state, it is impor-
tant to understand whether escape mechanisms differ among
tumors, and if so, whether there are hierarchically dominant
mechanisms that could be targeted therapeutically first. From
the therapeutic standpoint, it is unclear which of these mecha-
nisms contribute to a lack of response to the checkpoint
blockade and how they might interact—when they coexist—to
produce therapeutic resistance. By the reverse argument, it is
unclear which of these escape mechanisms can be overcome
by activation of lymphocytes through checkpoint blockade alone
and which continue to act as a barrier to attenuate or abolish the
effect of checkpoint blockade. It is likely that such mechanisms
do not have awell-defined hierarchy, but their logicmay be orga-
nized in networks. Although many of these resistance mecha-
nisms are pre-existing, others might emerge in response to
tumor adaptation to effective immune attack. Understanding
this complex system requires newmethods, including the devel-
opment of high-throughput experimental models that capture
the heterogeneity of tumors among patients and allow sys-
tems-pharmacology approaches producing large orthogonal
data sets as well as systems-biology analytical approaches
(Network, 2012).
Recognition of the complexity of biological networks has on
the one hand made it more difficult to identify appropriate thera-
peutic choices, but on the other hand, insights from systems
biology suggest a new way of thinking about treatment resis-
tance that may directly lead to new designs for trials. The tumor
microenvironment coopts robust tissue-repair mechanisms
developed to promote homeostasis after injury; this tissue-repair
response activates overlapping cellular and molecular mecha-
nisms promoting immune tolerance, angiogenesis, extracellular
remodeling, and tissue repair. Successful immunotherapy must
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Reviewoffer combinatorial strategies that make it impossible to block
T cell responses, either by eliminating an essential, nonredun-
dant central component or by simultaneously targeting multiple
components that are able to compensate for each other’s activ-
ity. Such knowledge can only be developed effectively with
experimental and analytical systems approaches and innovative
adaptive designs in clinical trials.
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